The Review of pharmacological treatment registered for obesity in Poland

Abstract

Introduction: Obesity is a persistent chronic condition. It is associated with an increased risk
of premature death and the development of accompanying diseases. According to statistical
data, half of the population struggles with excessive body weight, with one in five Poles
being obese. [2]
Aim: Our study aimed to evaluate the current literature on pharmacotherapy for obesity
available in Poland using the PubMed database. We emphasize the crucial importance of an
individualized patient approach to attain therapeutic success, aligning with the latest
guidelines and scientific research.
A brief description of the state of knowledge: In Poland, we have three registered
medications intended for the treatment of obesity: naltrexone/bupropion, liraglutide, and
orlistat. It's crucial that they assist in weight reduction, hence they should be used alongside
a proper diet and physical activity, not as the sole form of treatment. Using them assists in
achieving therapeutic targets determined in partnership with the patient, and lowers levels of
particular indicators linked to chronic inflammation and arterial issues. Moreover, they
diminish the chances of complications and early mortality due to the advancement of the
condition.
Summary: Obesity is a serious condition, and there should be no fear in incorporating
pharmacotherapy in patients with it. It is incredibly important to effectively treat this disease
and take proactive health measures, even at the stage of overweight, considering it as a
precursor to obesity.